Access
for All
Leaders of generic & biosimilar medicines are coming to Washington, DC
Leaders of generic & biosimilar medicines are coming to Washington, DC
Thank you to all who registered for the Association for Accessible Medicine’s annual meeting, Access! 2020. Unfortunately, but understandably, we have canceled the meeting scheduled for May 11-13 in Washington, DC.
Messages from keynote speakers who committed to Access! 2020
Access! 2020 brings together policymakers, influential speakers and industry leaders to chart the future of generics and biosimilars. Discussions center around the business, breakthroughs and politics that shape our industry. Additionally, attendees can meet with exhibitors, attend invaluable networking events and network with more than 600 attendees! It’s the opportunity to hear firsthand from world-renowned speakers and learn about where our industry is heading and what our future holds.
AAM’s annual business exposition offers a highly interactive and professional business environment in which industry vendors can meet generic and biosimilars industry executives. Building on the success of prior years, we offer our exhibitors abundant networking time with industry decision-makers. Showcase your company and share your solution while building your brand, connecting with new prospects, meeting with current clients and leaving with solid leads. One full plenary session pass and one expo pass are included in the booth price. Please note, AAM’s Access! Business Exposition sells out each year. Early registration is strongly advised.
Raise your company profile by participating in this prestigious event. For more information, regarding sponsorship levels and benefits contact Jennifer Soup at jennifer.soup@accessiblemeds.org.
For questions regarding registration for the Access! 2020 AAM Annual Meeting, please contact Aquera Agee at (202) 249-7138.
Whether you are an AAM member, general attendee, or exhibitor, come meet the leaders and decision-makers who are determining the future of generics and biosimilars.